Covid-19 RT PCR KIt(KRIVIDA NOVUS SARS Cov-2 RT-qPCR
- UID
- MFG/IVD/2022/000019_e1db73e8245378302617b844d592668f_2561750d762fa37e345652b29f9558c5
- Device class
- Class C
- Brand name
- Omicron Detection Kit
- License holder
- KRIYA Medical Technologies Private Limited
- Approving authority
- Central Drug Standard Control Organisation, South Zone
- Product information
- KRIVIDA Novus is a novel in-vitro 5-Plex RT-qPCR kit to detect SARS-CoV-2 using five different gene targets including RdRp, N-gene, S-gene, endogenous-Internal Control (Omicron Detection Kit) and an Omicron variant specific S gene probe. The uniqueness of the KRIVIDA Novus kit is that it can detect COVID-19 and simultaneously differentiate the other SARS-CoV-2 variants from Omicron in a single-tube assay. This significantly reduces the time taken for Omicron variant detection from 4 to 7 days by whole genome sequencing to 1 hour by this assay, which results in timely assessment of prognosis of the patient and assists in making decisions rapidly on quarantining the infected patients, thereby curtailing the community spread to a greater extent.
Covid-19 RT PCR KIt(KRIVIDA NOVUS SARS Cov-2 RT-qPCR is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID MFG/IVD/2022/000019_e1db73e8245378302617b844d592668f_2561750d762fa37e345652b29f9558c5. This device is marketed under the brand name Omicron Detection Kit. The license holder is KRIYA Medical Technologies Private Limited, and it is classified as Device Class Class C. The approving authority is Central Drug Standard Control Organisation, South Zone.
This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.